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Abstract Overexpression of a dominant-negative truncated
Kv1.1 (Kv1DN) polypeptide in the mouse heart resulted in
marked attenuation of a 4-aminopyridine (4-AP)-sensitive cur-
rent, IK;slow1. We used recombinant adeno-associated virus
(rAAV) as a vector for direct delivery of Kv1.5 into the mouse
myocardium in order to normalize the action potential duration
(APD) 6 months after injection. The injection of rAAV-Kv1.5
reconstituted the 4-AP-sensitive outward potassium currents,
shortened the APD, and eliminated spontaneous early afterde-
polarizations. Immunoblots detected the FL-Kv1.5 polypeptides
only in rAAV-Kv1.5-infected hearts. These data demonstrate
long-term expression of 4-AP-sensitive potassium currents in
ventricular myocytes by gene transfer using rAAV vector en-
codes Kv1.5.
/ 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Long QT syndrome is a genetically heterogeneous disease
caused primarily by marked reduction in the repolarizing cur-
rents due to mutations of the K or L subunits of voltage-gated
potassium channel genes [1,2]. These mutations reduce the
repolarizing potassium currents by abnormal tra⁄cking of
the K subunit or through the formation of non-functional
complexes in the membrane [3^5]. The overall e¡ect is pro-
longation of the action potential duration (APD), which trig-
gers the early afterdepolarizations (EADs), dispersion of re-
polarization, and refractoriness that underlie reentrant
ventricular arrhythmias such as torsade de pointes, syncope,
and sudden death [6].
We have created a mouse model for long QT phenotype by
overexpression of a truncated Kv1.1 polypeptide (Kv1N206-
Tag) in the hearts of transgenic mice (Kv1DN). Ventricular
myocytes derived from these mice have prolonged APD, while
the mice themselves exhibit prolonged QT interval in the sur-
face ECG and spontaneous and inducible polymorphic ven-
tricular tachycardias [7,8]. Studies of Kv1DN ventricular my-
ocytes showed the attenuation of a 4-aminopyridine (4-AP)-
sensitive outward potassium current IK;slow1 encoded by Kv1.5
[9]. Analysis of the cellular mechanism of the dominant-neg-
ative e¡ect of Kv1N206Tag established that the truncated
polypeptide trapped both Kv1.4 and Kv1.5 polypeptides in
the endoplasmic reticulum [10]. The downregulation of
IK;slow1 leads to electrical modulation, with the upregulation
of Kv2.1-encoded IK;slow2 at the apex of the left ventricle (LV)
[11]. This electrical remodeling leads to the formation of an
apex-to-base dispersion of repolarization that underlies the
reentrant arrhythmias [12].
Myocardial gene therapy represents a promising approach
to the treatment of inherited heart diseases. Previous studies
have shown e⁄cient adenovirus (AV)-mediated gene transfer
of numerous genes into the myocardium of several species,
including mice [13^15]. Recently, we have shown that direct
injection of adenoviral vectors expressing Kv1.5 into the heart
resulted in reconstitution of 4-AP-sensitive outward potassium
currents and shortening of the APD and the QT intervals [16].
However, the expression of AV-encoded proteins is only tran-
sient, due at least in part to a marked response of the immune
system to the vector and the lack of integration of the viral
vector with the host genome. Therefore, except for proof-of-
concept studies, AV-vectors are of limited use for the long-
term correction of somatic gene defects. Derived from a non-
pathogenic human parvovirus, recombinant adeno-associated
viral vectors represent an alternative to AV vectors for long-
term expression of genes in the myocardium. Several studies
have already established that these vectors can mediate long-
term expression of polypeptides in the heart [17^19]. In this
study we show for the ¢rst time that targeted regional infec-
tion with adeno-associated viral vectors encoding a voltage-
gated potassium channel, Kv1.5, induced expression of these
polypeptides 6 months after injection. This led to the restitu-
tion of the 4-AP-sensitive current, IK;slow1, shortening of the
APD, and elimination of the EADs in recombinant adeno-
associated virus (rAAV)-Kv1.5-infected Kv1DN ventricular
myocytes.
2. Materials and methods
2.1. Viral vectors
All animal studies were performed in accordance with the guidelines
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of the Harvard Medical Area Standing Committee on Animals after
approval by the Institutional Animal Care and Use Committee.
Kv1DN mice (age: 3^10 months) were infected with a single intra-
myocardial injection into the free wall of the LV of 25 Wl of either
vehicle (sterile, pyrogen-free 0.9% NaCl solution) or 25 Wl of an
rAAV-vector containing approximately 5U108 plaque-forming units
of a FLAG-tagged Kv1.5 under the control of a cytomegalovirus
(CMV) promoter.
2.2. Surgical procedure
After ketamine/xylazine anesthesia, mice were intubated and venti-
lated with 21% O2 and their body temperature was maintained with a
heating lamp. A midline skin incision was made, and a lateral thora-
cotomy was performed in the 4/5th intercostal space. After visualiza-
tion of the lateral free wall, 25 Wl of the solution (either rAAV or 0.9%
NaCl) was injected intramyocardially using an operating microscope.
E⁄cacy of injection was controlled by observing the brief paling and
swelling of the myocardium. After closure of the thorax and the skin,
mice were extubated and recovered on heated bedding.
2.3. Animals and cell isolation
Single myocytes were isolated from the LV free wall of transgenic
mice (Kv1DN) injected either with rAAV or 0.9% NaCl using the
Langendor¡ technique. Low Ca2þ tyrode solution containing 20^30
mM 2,3-butanedione monoxime was used to suppress the contractile
activity of the myocytes during the isolation procedure.
2.4. Solutions and chemicals
In all experiments, the following extracellular physiological solution
was used (in mM): 135 NaCl, 5.4 KCl, 0.33 NaH2PO4, 1 MgCl2,
1 CaCl2, 10 HEPES, and 10 glucose (pH was adjusted to 7.35 with
NaOH). The L-type Ca2þ and Naþ channels were blocked by the
application of 2 mM CoCl2 and 20 WM tetrodotoxin (TTX), respec-
tively. The pipette solution contained (in mM): 140 KCl, 1 MgCl2, 10
HEPES, 5 EGTA, 5 Mg2ATP, 0.1 GTP (pH=7.2 with KOH). The
contamination by ATP-sensitive potassium current was avoided by
using a high concentration of ATP in the intracellular solution. Stock
solutions of TTX, 4-AP, and tetraethylammonium (TEA) in 2^10 mM
concentration were prepared.
Fig. 1. Infection with rAAV-Kv1.5 restitutes 4-AP-sensitive currents. A family of outward potassium currents in myocytes derived from vehicle-
injected (A^D) or rAAV-Kv1.5-injected (E^H) hearts. Current traces were recorded before (A,E) and after (B,F) application of 50 WM 4-AP.
The 4-AP-sensitive currents are shown in C and G. D and H depict the I^V relationships of peak currents (F), 4-AP-sensitive (R) and TEA-
sensitive currents (b) observed in myocytes derived from vehicle or rAAV-Kv1.5 (n=8^10), respectively. Note the small 4-AP-sensitive currents
in vehicle-treated myocytes. Scale bars identically refer to all current traces.
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2.5. Electrophysiology and data analysis
Membrane currents were recorded using the whole-cell mode of the
patch-clamp technique [20]. The patch electrodes were pulled (P87;
Sutter Instruments, USA) from 1.5-mm diameter borosilicate glass
capillaries (WPI). Their resistances were 0.8^2 M6 when ¢lled with
a standard pipette solution. An Axopatch 200B ampli¢er in combina-
tion with pClamp 8.1 software and DigiData 1322A (Axon Instru-
ments, USA) were used for data acquisition. In this study, cell capaci-
tances of vehicle- and rAAV-Kv1.5-injected myocytes were 166Q 17
pF (n=10) and 198Q 31 pF (n=8), respectively (Ps 0.05). Raw traces
are shown without correction for leakage currents. Experiments show-
ing a signi¢cant leak (recognized after depolarizing steps) were dis-
carded. Data analysis and graphs were obtained using Clamp¢t 8.1
(Axon Instruments), Excel 2000 (Microsoft), and Origin 7.0 software
(Microcal). The data are presented as the meanQS.E.M., and n cor-
responds to the number of experiments. Student’s paired t-test was
used to examine the di¡erence between data groups; P6 0.05 was
considered signi¢cant.
3. Results
3.1. Restitution of the 4-AP-sensitive current
The rAAV-Kv1.5 or vehicle was injected into the free wall
of the LV. Six months after the injection, the mice were sac-
ri¢ced and ventricular myocytes derived from this region were
studied. In both vehicle- and rAAVKv1.5-treated hearts, we
observed signi¢cant pericardial ¢brosis secondary to the pro-
cedure (data not shown). We ¢rst characterized myocytes de-
rived from vehicle-injected hearts (Fig. 1A^D). Similar to the
¢ndings of previous studies [7], vehicle-treated Kv1DN myo-
cytes (Fig. 1A) exhibited a transient outward current (Ito)
followed by a slowly inactivating current (mainly IK;slow2)
[11]. The I^V relationship of the peak current of myocytes
from vehicle-injected hearts was linear, with a mean value of
54.5Q 8 pA/pF at +60 mV (Fig. 1D). Application of 50 WM
4-AP did not signi¢cantly reduce the amplitude of outward
current in control myocytes (Fig. 1B), and the density of
4-AP-sensitive current at +60 mV (Fig. 1C,D) was 3.1Q 0.3
pA/pF (n=8). This current accounted for 5.8 Q 1% of the total
current.
We next compared the outward currents detected in these
cells to those in rAAV-Kv1.5-injected hearts (Fig. 1E^H). On
the basis of our studies in vehicle-injected hearts (Fig. 1A^D),
cells displaying 4-AP-sensitive current v 15% of the total out-
ward potassium current at +60 mV were considered infected
with rAAV-Kv1.5 (Fig. 1G). Of 30 cells isolated from virus-
injected LV free wall, 10 met these criteria (Fig. 1E^H). These
rAAV-Kv1.5-infected cells appeared to express a new compo-
nent that reconstituted the total outward currents to a pattern
similar to that recorded from the wild-type adult murine ven-
tricular myocytes [7]. The I^V relationship of the peak current
amplitude of rAAV-Kv1.5-infected cells was linear, with a
mean value of 31.4 Q 3.5 pA/pF at +60 mV, signi¢cantly lower
than that of vehicle-treated hearts (P6 0.05). The density of
the 4-AP-sensitive current in rAAV-Kv1.5-infected myocytes
ranged from 3.1 to 18.4 pA/pF, with a mean value of 9.8 Q 2
pA/pF, which represents 27.5Q 4.3% of the total outward cur-
rent, signi¢cantly higher than that observed in control myo-
cytes (P6 0.01). The inactivation of the 4-AP-sensitive current
was best ¢tted with a single exponential function, with a time
constant of 2.1 Q 0.5 s (n=4), which di¡ered from that of
wild-type 4-AP-sensitive current, revealing that these currents
are di¡erent from the endogenous ones. The reduction in peak
current despite the upregulation in the 4-AP-sensitive currents
correlated with a signi¢cant reduction in Ito;f from 43.8Q 8.3
pA/pF (n=10) in control myocytes to 23.3 Q 3.5 pA/pF (n=8)
in rAAV-Kv1.5 myocytes (P6 0.01). Of note, the TEA-sensi-
tive current (6.8 Q 0.5 pA/pF) did not di¡er between the two
groups and represented 15% of the total current (Fig. 1D and
H). Thus, the Kv2.1-encoded current was not modi¢ed in
these groups [11].
To further prove that the rAAV-Kv1.5-infected hearts ex-
press the FLAG-tagged Kv1.5 polypeptides, we used anti-
FLAG antibodies to precipitate the FL-Kv1.5 polypeptides
from these hearts. The immunoprecipitates were then sub-
jected to SDS^PAGE and blotted with anti-FLAG antibodies.
Fig. 2A depicts the precipitates obtained from four di¡erent
hearts infected with rAAV-Kv1.5. All these hearts express
multiple bands, with an apparent molecular mass of approx-
imately 85 kDa. These polypeptides are absent from vehicle-
injected hearts. The multiple bands likely re£ect post-transla-
tional modi¢cations such as glycosylation. Collectively, our
data reveal that injection of rAAV-Kv1.5 induced long-term
expression of the Kv1.5 polypeptides associated with the res-
titution of 4-AP-sensitive currents.
Fig. 2. Expression of exogenous Kv1.5 polypeptides and properties
of evoked APs. A: Immunoblot analysis detected the expression of
Kv1.5 polypeptide only in rAAV-Kv1.5-infected hearts (the four
lanes represent four di¡erent animals), not those injected with ve-
hicle. The multiple bands likely re£ect posttranslational modi¢ca-
tions of the channel polypeptides. B: Morphology of APs in ventric-
ular cells isolated from both hearts injected with vehicle (thick line)
and rAAV-Kv1.5 (thin line). C: APD at 90% repolarization in two
groups (n=14, P6 0.001).
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3.2. Properties of APs
The functional consequences of Kv1.5 restitution were in-
vestigated by examining AP waveforms in myocytes from
both vehicle- and rAAV-Kv1.5-injected hearts. Fig. 2B depicts
a typical AP of control cardiomyocyte versus that of a rAAV-
Kv1.5-infected cell. The APD90 of myocytes derived from
rAAV-Kv1.5-infected mice was signi¢cantly shorter (31.6 Q
3.4 ms, n=14) than that of myocytes from hearts injected
with vehicle (70.4 Q 9.2 ms, n=14, P6 0.001) (Fig. 2C). The
cells from vehicle-injected mice had a resting membrane po-
tential (RMP) similar to that of cells from hearts infected with
rAAV-Kv1.5 (367.3 Q 1.9 mV, n=14 vs. 372.9 Q 2.2, n=14,
Ps 0.05). The AP amplitudes also did not di¡er on average
between the vehicle-injected (386.5 Q 3.1 mV, n=23) and
rAAV-Kv1.5-infected myocytes (394.6Q 4.2 mV, n=14,
Ps 0.05).
3.3. rAAV-Kv1.5 abolishes EADs in Kv1DN mice
We next studied whether the treatment with rAAVKv1.5
modi¢ed the arrhythmogenic phenotype of Kv1DN ventricu-
lar myocytes. During the entire study, most experiments were
conducted in the standard physiological solution in order to
record both the RMP and the APs. Fig. 3A depicts the spon-
taneously ¢ring APs recorded from a cardiomyocyte derived
from a vehicle-injected heart. These APs exhibited a slow rate
of eight cycles per min. The repolarization phase was dramat-
ically delayed, and at 340 mV, oscillations in the membrane
potential could subsequently be observed; these are clearly
illustrated in an expanded time scale (Fig. 3B). By contrast,
we could not detect any EADs in 14 cells infected with rAAV-
Kv1.5 (Fig. 3C). Thus, the long-term expression of rAAV-
Kv1.5 in myocytes located near the injection site shortened
the APD and abolished the EADs.
4. Discussion
We investigated the e¡ect of rAAV-Kv1.5-mediated gene
transfer into a small area of the myocardium of transgenic
mice that overexpress a truncated potassium channel,
Kv1N206Tag. We hypothesized that the potent induction of
Kv1.5 under the regulation of the CMV promoter would shift
the balance from non-functional heterotetramers of Kv1.5
and Kv1N206Tag polypeptides towards functional Kv1.5 ho-
motetramers. Here we demonstrate for the ¢rst time the long-
term expression of a voltage-gated potassium channel in the
heart using an adeno-associated viral vector. Similar to our
previous observations, at one week after infection with adeno-
viral vector encoding Kv1.5 [16], we demonstrate that the
AAV-encoded Kv1.5 also enhanced the 4-AP-sensitive current
IK;slow1 6 months after infection, whereas in myocytes derived
from vehicle-treated hearts, the 4-AP-sensitive current re-
mained attenuated. It is interesting that this current had a
slower inactivation rate, suggesting that the functional com-
plexes in the membrane lack additional subunits.
The enhancement of this current caused a signi¢cant short-
ening of the APD90 and the elimination of EADs. We ob-
served fewer cell-to-cell variations in the density of the
4-AP-sensitive currents in the present study than in our pre-
vious study using adenoviral vectors encoding Kv1.5.
Although Western blot analyses were su⁄cient to detect the
abundance of FL-Kv1.5 polypeptides in AV-treated hearts,
here we had to combine immunoblots with immunoprecipita-
tion to detect the markedly smaller amounts of rAAV-induced
channel polypeptides. The reduction in Ito;f compared with
vehicle-treated hearts likely re£ects either the e¡ect of long-
term expression of Kv1.5 in the myocytes or, more likely, the
¢brosis and in£ammation induced by treatment with rAAV
vectors. To discern the role of the adeno-associated viral vec-
tor from that of Kv1.5, we injected mice with AAV vector
encoding green £uorescence protein (GFP) as an additional
control. Myocytes derived from these mice were harvested
6 months after injection, but we could not detect the expres-
sion of the GFP (as detectable by green £uorescence above
background) in these cells. Thus, we could not study AAV^
GFP-infected cells as an additional control. This contrasts
with our experience with AV^GFP, in which we could detect
substantial GFP expression 7^10 days after injection [16].
Thus, we cannot discern whether the vector rAAV itself or
the rAAV-Kv1.5 was the cause of the downregulation of Ito;f .
In summary, we demonstrate that in vivo infection of
Kv1DN myocardium with rAAV-Kv1.5 restitutes the 4-AP-
sensitive current and shortens the APD. The shortening of the
APD abolished the EADs. Thus, targeted expression of func-
tional channels may lead to new approaches for therapeutic
interventions in patients with cardiac arrhythmias and long
QT syndrome.
Fig. 3. Spontaneous EADs. A: Abnormal APs recorded from single
left ventricular cell of vehicle-injected Kv1DN mouse heart. B: Ran-
domly chosen AP (*) in an expanded time scale. Note the triggered
EADs (in this example there are nine EADs). Scale bars are shown.
C: Incidence of EADs in vehicle vs. rAAV-Kv1.5 infected myo-
cytes.
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